CENTRAL LABORATORIES WHITE PAPERS & ARTICLES

• Paper COAs In 2026? It's Not "Cheaper," It's Riskier

  Paper-based assessments add operational and regulatory risk — from poor data quality to delayed insights — quietly threatening timelines, compliance, and trial confidence.

• Medical Device Clinical Trials: Key Considerations For Sponsors And CROs

  Medical device trials must align risk class, regulations, and study design. Strong oversight, data, and proactive safety planning support reliable evidence and market approval.

• A Guide To Medical Coding In Clinical Trials

  Medical coding transforms free-text clinical data into standardized terminology, enabling consistent analysis, safety monitoring, and regulatory review. Clear guidelines and quality control help reduce variability and protect data integrity across the entire clinical trial lifecycle.

• The Patient Experience Paradox: eCOA Strategy Overhaul

  European regulatory shifts now require the systematic integration of patient data. Success depends on aligning clinical and market access strategies through rigorous evidence generation.

• AI Needs A Home: Inside The Workflows That Drive Trials

  Move beyond fragmented digital tools. Learn how a governed execution layer transforms AI into a collaborator, streamlining trial decisions and creating a traceable record of human-AI insight.